First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial

CONCLUSIONS: The investigational regimen did not improve the primary outcome for the intention-to-treat population but might benefit small subgroups of patients with previously untreated, metastatic microsatellite-stable colorectal cancer.TRIAL REGISTRATION: ClinicalTrials.gov number, NCT03388190 (02/01/2018).PMID:38664577 | DOI:10.1038/s41416-024-02696-6

Source: Cancer Control - April 25, 2024 Category: Cancer & Oncology Authors: Anne Hansen Ree J ūratė Šaltytė Benth Hanne M Hamre Christian Kersten Eva Hofsli Marianne G Guren Halfdan Sorbye Christin Johansen Anne Neg ård Tonje Bj ørnetrø Hilde L Nilsen Jens P Berg Kjersti Flatmark Sebastian Meltzer Source Type: research